Nativis Publishes Abstract on Voyager System for Patients with rGBM at 2017 ASCO Annual Meeting

Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is a traveler-first driven platform giving healthcare professionals the power to make decisions in their careers that they haven't been able to in the past.

Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.

Interim results presented for first-in-human study in first of 2-stage study

Nativis, Inc., today announced the release of an abstract on its Nativis Voyager® system for use in patients with recurrent glioblastoma multiforme (rGBM). The abstract will be published online during the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2017, in Chicago, IL. Abstracts can be found here.

The Nativis Voyager system is a non-invasive investigational device that delivers ultra-low radio frequency energy (ulRFE™) profiles to the brain. The ulRFE profiles are derived from changes in molecular electrostatic surface potential. The Voyager system is being studied in a first-in-human study to assess the safety and feasibility of treatment for recurrent glioblastoma multiforme.

In the publication entitled “A Feasibility Study of the Nativis Voyager™ System in Patients with Recurrent Glioblastoma Multiforme (GBM): Interim results of first-in-human study,” the authors, Garni Barkhoudarian, Charles Cobbs, Edward McClay, Brian Vaillant, J. Paul Duic, L. Burt Nabors, Benjamin M. Ellingson, Deborah Sheffield, Santosh Kesari, highlighted the interim results of the first part of a 2-stage study. This first study enrolled 14 patients at four clinical trial sites across the United States, in which 11 subjects were followed per protocol, with 3 subjects dropping out for reasons not associated with the study. In the first two months of treatment, 2 of the 11 subjects were Avastin-naïve and exhibited a partial response. After 6 cycles (24 weeks) of treatment, the local sites reported 2 patients were progression free. No serious adverse events associated with the investigational therapy were reported.

“We are honored to have our first-in-human study recognized by ASCO as we continue to pioneer our novel ulRFE technology,” commented Chris Rivera, Nativis President and Chief Executive Officer. “The interim data from this feasibility study provide an encouraging outlook for the Voyager system, which appears to be feasible and safe for the treatment of recurrent GBM. With these data in hand, we look forward to moving forward into the second and final stage of the study.”



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles